Navigation Links
Jennerex Appoints Gregory W. Schafer as Chief Financial Officer

SAN FRANCISCO, June 22 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Gregory W. Schafer as senior vice president and chief financial officer.  Mr. Schafer will be responsible for the Company's finance, accounting, planning, investor relations and treasury functions.

"Greg's finance and operations experience in the life sciences industry make him an ideal fit for Jennerex at this pivotal time for the company," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "Importantly, Greg's successful track record in raising capital and his involvement in bringing products through clinical development to the market will make him invaluable as we move JX-594 into Phase 3 clinical trials.  Additionally, we are grateful to Ian Malone, who has been a significant contributor to Jennerex as our CFO in recent years and who has now transitioned into an advisory capacity."

Mr. Schafer brings more than 20 years of broad functional and strategic leadership expertise to Jennerex and has raised over $600 million in public and private transactions to fund biotechnology product development and commercialization activities.  Most recently, he served as chief financial officer of Onyx Pharmaceuticals, Inc., where he was responsible for finance, accounting, risk management, and strategic and operational planning.  Prior to Onyx, he served as chief financial officer and vice president of finance for Cerus Corporation, where he played a key role in transitioning the company from early-stage development to a commercial enterprise with an approved product.  Prior to Cerus, Mr. Schafer worked as a management consultant for Deloitte and Touche, LLP and as an engineer specializing in biologics manufacturing.  Mr. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company.  He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer — an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Busan, South Korea.  For more information about Jennerex, please visit

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Announces Presentations at Upcoming Conferences
2. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
3. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
8. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
9. EPEMED, the European Personalised Medicine Association, Appoints Executive Director
10. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
11. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
Post Your Comments:
(Date:11/24/2015)... Calif. , Nov. 24, 2015 /PRNewswire/ ... leader in non-invasive genetic testing and the ... that it will present at the 27 ... York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, ... Company,s financial results, business activities and financial ...
(Date:11/24/2015)... 24, 2015  In the pharmaceutical industry, companies want ... to quickly uncover new insights, tactics and strategies that ... --> However, organizations often find it ... and ensure that all rules and regulations are met ... major barrier to efficiently launching market research projects is ...
(Date:11/24/2015)... , Nueva York , 24 ... Devices (ABD), fabricante del Avery Breathing Pacemaker System, ... Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... El doctor Jonzon es un fisiólogo y ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also ... many people who find their cholesterol levels and weight are creeping up are more ... they don’t have any of the other symptoms. , Thyroid hormone plays a major ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... lower prices in an early celebration of the early holiday shopping season. Starting ... $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD ... benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology ... by a dentist in Gettysburg, PA . From routine visits to cosmetic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now visit ... ON practice. Dr. Williams has been providing dental service for over 34 years, and ... can lead to a variety of complications if they are not replaced quickly, including ...
Breaking Medicine News(10 mins):